| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 12/29/2005 | US20050287219 Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
| 12/29/2005 | US20050287212 Oral delivery system comprising a drug/polymer complex |
| 12/29/2005 | US20050287211 Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition |
| 12/29/2005 | US20050287208 Cross-linked powered/microfibrillated cellulose II |
| 12/29/2005 | US20050287202 Compound |
| 12/29/2005 | US20050287200 Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
| 12/29/2005 | US20050287198 Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
| 12/29/2005 | US20050287195 Transdermal drug delivery systems |
| 12/29/2005 | US20050287194 Permeation enhancing compositions for anticholinergic agents |
| 12/29/2005 | US20050287189 Antitumor, anticancer agents; particles or coils or stents coated solid-phase agent comprising a binding agent comprising collagen are directed to target vasculature, such as the vasculature of solid tumor masses or aneurysms |
| 12/29/2005 | US20050287181 A mixture of propylene carbonate and glycerol formal in a ratio of 90:10-10:90 containing hydroxypropylmethylcellulose, a phospholipid and a fungicide; time-released agent; sustained'release; veterinary medicine; sustained release; topical, otic, and ophthalmic |
| 12/29/2005 | US20050287180 Phospholipid compositions and methods for their preparation and use |
| 12/29/2005 | US20050287179 Use of ethyl lactate as an excipient for pharmaceutical compositions |
| 12/29/2005 | US20050287159 Treatment methods for eotaxin mediated inflammatory conditons |
| 12/29/2005 | US20050287155 Active agent has been modified by attachment of cell membrane-impermeabilizing group so that, if active agent so modified is cleaved from conjugate in blood plasma instead of inside target cell, the cell membrane-impermeabilizing group prevents or limits entry of modified active agent into cells |
| 12/29/2005 | US20050287154 Autophilic antibodies and method of making and using same |
| 12/29/2005 | US20050287153 Serum albumin binding peptides for tumor targeting |
| 12/29/2005 | US20050287149 Human monoclonal antibodies against bacillus anthracis protective antigen |
| 12/29/2005 | US20050287145 Compositions and methods for producing vascular occlusion |
| 12/29/2005 | US20050287141 Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| 12/29/2005 | US20050287139 Wound healing |
| 12/29/2005 | US20050287135 Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
| 12/29/2005 | US20050287114 Water-soluble polymeric bone-targeting drug delivery system |
| 12/29/2005 | US20050287113 two polymer molecules attached at a single site on a biomolecule; water soluble and have beneficial pharmacological properties, such as reduced immunogenicity and increased circulation time |
| 12/29/2005 | US20050287110 Cationic graft-compolymer for non-viral gene delivery vector |
| 12/29/2005 | US20050287097 hydrophobic polymer includes repeating pyrrolidone/alkylene groups containing 10 or more carbon atoms, a hydrophilic polymer including polyacrylic acid, maleic acid-methyl vinyl ether copolymer, starch, cellulose, polyvinyl alcohol, dextrans/yclodextrin; cosmetics; skin |
| 12/29/2005 | US20050287087 includes an aqueous base of water, methylcellulose and citric acid, pharmaceutically active or cosmetic agent or nutritional agent; drug delivery for treating cardiovascular and psychological disorders, vision defects, inflammation, infections and for cartilage repair and birth control |
| 12/29/2005 | US20050287079 Combinations of formoterol and fluticasone propionate for asthma |
| 12/29/2005 | US20050287076 Compounds for use as surfactants |
| 12/29/2005 | US20050287074 Matrix metalloproteinase inhibitors |
| 12/29/2005 | US20050287067 Compounds of the inventions of guanylyl cyclase C |
| 12/29/2005 | US20050284812 Process for preparing water soluble diterpenes and their applications |
| 12/29/2005 | CA2608862A1 Silk-based drug delivery system |
| 12/29/2005 | CA2575101A1 Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use |
| 12/29/2005 | CA2570258A1 Bi- or tetra-guanidino-biphenyl compounds as small molecule carriers |
| 12/29/2005 | CA2569726A1 Hydrophobic ophthalmic compositions and methods of use |
| 12/29/2005 | CA2568601A1 Peptide-based compounds |
| 12/29/2005 | CA2568388A1 Preparation of macromolecular conjugates by four-component condensation reaction |
| 12/29/2005 | CA2567684A1 Composition in the form of a spray comprising a combination of clobetasol propionate and calcitriol, an alcohol phase and an oily phase |
| 12/29/2005 | CA2567683A1 Composition in spray form comprising a combination of a corticoid and a vitamin d derivative in an oily phase |
| 12/29/2005 | CA2567636A1 Composition for the treatment of psoriasis comprising a silicone agent, a corticosteroid and vitamin d or a derivative thereof |
| 12/29/2005 | CA2565972A1 Ex-vivo application of solid microparticulate therapeutic agents |
| 12/28/2005 | EP1609852A1 Bifidobacteria and preparations containing them |
| 12/28/2005 | EP1609482A1 Drug for treating hemophilia and method of treating hemophilia using the same |
| 12/28/2005 | EP1609481A1 Injectable pharmaceutical compositions comprising sodium diclofenac, beta-cyclodextrin and a polysorbate |
| 12/28/2005 | EP1609478A1 Exendin agonist peptide formulations |
| 12/28/2005 | EP1609470A1 Nasal delivery of apomorphine |
| 12/28/2005 | EP1609468A2 A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis |
| 12/28/2005 | EP1609465A1 Ophthalmic drug delivery system using polymer micell |
| 12/28/2005 | EP1608688A2 Branched water-soluble polymers and their conjugates |
| 12/28/2005 | EP1608687A1 Novel cyclodextrin derivatives, method for the preparation thereof and use thereof for the solubilization of pharmacologically active substances |
| 12/28/2005 | EP1608684A2 Amphiregulin antibodies and their use to treat cancer and psoriasis |
| 12/28/2005 | EP1608680A2 Glp-2 derivatives |
| 12/28/2005 | EP1608408A1 Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same |
| 12/28/2005 | EP1608407A2 Dispersible formulation of an anti-inflammatory agent |
| 12/28/2005 | EP1608406A1 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| 12/28/2005 | EP1608383A1 A formulation comprising a bacterial strain |
| 12/28/2005 | EP1608378A1 Prostaglandin compositions and their use for the treatment of vasospasm |
| 12/28/2005 | EP1608372A2 Compositions containing fentanyl |
| 12/28/2005 | EP1608362A1 Stabilized pharmaceutical preparation comprising an amorphous active substance |
| 12/28/2005 | EP1608356A2 Compositions for treating microbial and parasitic infections in cattle and other animals |
| 12/28/2005 | EP1608353A1 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| 12/28/2005 | EP1608346A1 Alpha-hydroxy acid ester drug delivery compositions and methods of use |
| 12/28/2005 | EP1608345A1 Capsules with delayed release of the capsule contents for oral administration |
| 12/28/2005 | EP1608344A2 Oral formulations of cladribine |
| 12/28/2005 | EP1608343A2 Cladribine formulations for improved oral and transmucosal delivery |
| 12/28/2005 | EP1608340A2 A method of preparing gas-filled polymer matrix microparticles useful for delivering drug |
| 12/28/2005 | EP1608338A1 Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| 12/28/2005 | EP1608335A1 Controlled release system containing saccharose acetate isobutyrate |
| 12/28/2005 | EP1608289A2 Devices, methods, and compositions to prevent restenosis |
| 12/28/2005 | EP1432450B1 Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
| 12/28/2005 | EP1401502B1 Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer |
| 12/28/2005 | EP1330258B1 Kahalalide f formulation |
| 12/28/2005 | EP1299352B1 Compounds to treat alzheimer's disease |
| 12/28/2005 | EP1294375B1 Treatment of seborrheic dermatitis |
| 12/28/2005 | EP1251843B1 Compositions for delivery of a cortisol antagonist |
| 12/28/2005 | EP1246627B1 Polyanhydrides with biologically active degradation products |
| 12/28/2005 | EP1218023B1 Method for calming human beings using personal care compositions |
| 12/28/2005 | EP1161418B1 1-acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors |
| 12/28/2005 | EP1123114B1 Virus-like particles for the induction of autoantibodies |
| 12/28/2005 | EP1117411B1 Process for the preparation of oral pharmaceutical compositions comprising biphosphonates |
| 12/28/2005 | EP1085909B1 A complex of alpha-fetoprotein (AFP) and a polyunsaturated fatty acid derivative for the treatment of immune deficiencies |
| 12/28/2005 | EP1082107B8 Controlled release lipoic acid |
| 12/28/2005 | EP1053238B1 Therapeutic compounds |
| 12/28/2005 | EP1021204B1 Bioadhesive compositions and methods for topical administration of active agents |
| 12/28/2005 | EP1011717B1 Arginine deiminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
| 12/28/2005 | EP0971747B1 Contrast agents |
| 12/28/2005 | EP0954291B1 Soluble form osmotic dose delivery system |
| 12/28/2005 | EP0925061B1 Compositions comprising microparticles of water-insoluble substances and method for preparing same |
| 12/28/2005 | EP0797589B1 Peptides usable as vectors for the intracellular addressing of active molecules |
| 12/28/2005 | EP0642585B1 Activation of oligomerizing receptors by using fused receptor ligands |
| 12/28/2005 | CN1714116A Modified bio-related substance, process for producing the same, and intermediate |
| 12/28/2005 | CN1713924A Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
| 12/28/2005 | CN1713923A Pharmaceutical compositions having a modified vehicle |
| 12/28/2005 | CN1713920A Modified transferrin fusion proteins |
| 12/28/2005 | CN1713919A Novel use of erythropoietin in heart diseases |
| 12/28/2005 | CN1713899A Transdermal therapeutic system with fentanyl or related substances |
| 12/28/2005 | CN1713895A Increased-dosage nelfinavir tablet and method of making same |
| 12/28/2005 | CN1713894A Method for preparing a compound of interaction of active substances with a porous support using supercritical fluid |
| 12/28/2005 | CN1713890A Controlled release depot formulations |